Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults

BACKGROUND:Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failures, for regimen simplification or to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Pediatric infectious disease journal 2016-09, Vol.35 (9), p.e271-e274
Hauptverfasser:	Foca, Marc, Yogev, Ram, Wiznia, Andrew, Hazra, Rohan, Jean-Philippe, Patrick, Graham, Bobbie, Britto, Paula, Carey, Vincent J, King, Jennifer, Acosta, Edward P, Cressey, Tim R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anti-HIV Agents - blood Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - therapeutic use Child Darunavir - therapeutic use Drug Interactions Drug Therapy, Combination Female HIV Infections - drug therapy Humans Male Rilpivirine - blood Rilpivirine - pharmacokinetics Rilpivirine - therapeutic use Ritonavir - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND:Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failures, for regimen simplification or to minimize toxicity. Darunavir/ritonavir (DRV/r) administered once daily is also increasingly used in adolescents and may alter RPV pharmacokinetics (PK). We evaluated the PK interactions between RPV and DRV/r once daily in adolescents and young adults. METHODS:Human immunodeficiency virus–infected subjects 12 to
ISSN:	0891-3668 1532-0987
DOI:	10.1097/INF.0000000000001214